NexPoint Real Estate Finance (NREF) Q2 FY26 earnings call: guidance and Q&A

How does management view the long-term portfolio allocation between life sciences and multifamily, especially given the recent increase in life science exposure and the AI theme?

Management aims for life science/advanced manufacturing to be about one-third of the portfolio and residential around 50% in a normalized environment. The Alewife life science asset was a unique opportunity, and capital returned from its expected Q4 refinancing will likely be redeployed into residential assets.

“I think in a normalized environment, we'd probably like to keep life sciences to be about a 1/3 -- or I'd say life science and advanced manufacturing, kind of biomanufacturing, those type of assets in around 1/3 of the pie chart. Obviously, in the recent kind of 12 to 18 months, Alewife is a one-off, pretty special opportunity that we were able to take advantage of.”

asked by Crispin Love · answered by Matthew McGraner

Given that CAD has been above the dividend but EAD has been below for several quarters, when does management expect both EAD and CAD to sustainably cover the dividend, and is the current dividend level comfortable?

Management is comfortable with the current dividend level due to strong CAD coverage, which is their primary metric. They expect EAD and CAD to converge over time, noting that CAD has increased in recent quarters due to accretive redeployment of capital from preferred stock offerings.

“We're definitely comfortable with the CAD coverage, which is our gold standard when it comes to distributions and when we discuss with the Board those opportunities for quarterly distributions. And over time we do think both EAD and CAD will converge, and what you've seen, too, is the increase in CAD over the past few quarters, as we discussed in prior calls, due to the redeployment accretively into investments via using proceeds from our Series B and now Series C preferred raising.”

asked by Crispin Love · answered by Paul Richards

What is the underlying credit performance in the multifamily book, specifically for preferred equity and B-Piece exposure?

The multifamily credit performance is strong due to a focus on agency-quality assets, largely avoiding non-bank floating-rate bridge loans. Most preferred equity collateral is behind agency loans. No credit provisions or leaks have been observed in either the B-Piece or preferred equity books. Management is constructive on the transaction market and supply/demand setup for the next few quarters.

“I think we benefited from largely investing and focusing on assets that were agency quality. So Fannie and Freddie underwritten assets that were first screened by a JLL, Walker, et cetera, and then underwritten by our team. So we did very little of sort of the non-bank, floating-rate bridge loans that I think some of our peers have done and gotten in trouble with.”

asked by Jade Rahmani · answered by Matthew McGraner

Beyond the strong performance of Alewife, what is the outlook for the rest of the life science exposure, given that the sector remains quite challenged?

The broader life science exposure continues to sequentially improve, with tours and tenant-in-market lists up 30% from Q1 to Q2, and Q3 tracking ahead. Management believes their assets are well-located and first-to-fill. They also noted that most of their life science exposure was originated in the 'distressed era' of 2024-2026 at reset bases, avoiding the credit issues seen with 2021-2022 vintage loans.

“The broader exposure on our life science book continues to sequentially get better. Tours and our TIMs, the tenants in the market list, sequentially over Q1 into Q2, were up 30%. And more in works. We're already seeing in July, even with the holiday soaking up the first two weeks, that the third quarter is tracking to be ahead in terms of tour activity.”

asked by Jade Rahmani · answered by Matthew McGraner